Decision to dissolve and commence special liquidation of a consolidated subsidiary, risk that receivables will be uncollectible, and transfer of the business to the Company
アクセルメディカ株式会社 (the filing company's wholly owned subsidiary); AXEL MARK INC. (the entity taking over the business)
Beauty & Wellness business and cosmetics and other products relating to the Company's proprietary brand "≒4.7"
Revenue has consistently fallen substantially below plan since establishment and operating losses have continued; the company was wholly dependent on loans from the Company; and, after becoming insolvent, the ¥3,000,000 loan to the business partner fell into arrears, further worsening its cash position.
Loans of ¥112.5 million (as of 17 September 2026). Most of the loans are likely to be uncollectible, and the full amount, including the remaining balance, is expected to be recognized as a provision for doubtful accounts. Special losses, including business restructuring losses, have not yet been determined.
There is a possibility that special losses, including business restructuring losses, will be recognized in the consolidated financial statements for the fiscal year ending September 2026. An additional provision for the loans is expected to be recognized in the non-consolidated financial statements for the fiscal year ending September 2026.
If it becomes necessary to revise the consolidated earnings forecast for the fiscal year ending September 2026, the Company will promptly announce the revision. The earnings forecast for the fiscal year ending September 2027 is scheduled to be announced when the financial results for the fiscal year ending September 2026 are released, incorporating the impact of this matter.
Loans of ¥112.5 million (as of 17 September 2026, owed by アクセルメディカ株式会社)
Related procedures
Special liquidation under the Companies Act
Company response
The specific timing of resumption has not been determined at this time.
アクセルメディカ株式会社 is scheduled to be excluded from the scope of consolidation when its liquidation is completed. AXEL MARK INC. will take over the Beauty & Wellness business and plans to rebuild it after completing preparations, including obtaining a new manufacturing and marketing license.
If it becomes necessary to revise the earnings forecast for the fiscal year ending September 2026, the Company will promptly announce the revision. The earnings forecast for the fiscal year ending September 2027 is scheduled to be announced when the financial results for the fiscal year ending September 2026 are released.
| Item | Details |
|---|---|
| Event name | Decision to dissolve and commence special liquidation of a consolidated subsidiary, risk that receivables will be uncollectible, and transfer of the business to the Company |
| Date of occurrence | 17 September 2026 (scheduled dissolution date of アクセルメディカ株式会社) |
| Subject Entity | アクセルメディカ株式会社 (the filing company's wholly owned subsidiary); AXEL MARK INC. (the entity taking over the business) |
| Target Locations / Products | Beauty & Wellness business and cosmetics and other products relating to the Company's proprietary brand "≒4.7" |
| Cause | Revenue has consistently fallen substantially below plan since establishment and operating losses have continued; the company was wholly dependent on loans from the Company; and, after becoming insolvent, the ¥3,000,000 loan to the business partner fell into arrears, further worsening its cash position. |
| Amount of Impact on Business Performance | Loans of ¥112.5 million (as of 17 September 2026). Most of the loans are likely to be uncollectible, and the full amount, including the remaining balance, is expected to be recognized as a provision for doubtful accounts. Special losses, including business restructuring losses, have not yet been determined. |
| Accounting period in which recognized | There is a possibility that special losses, including business restructuring losses, will be recognized in the consolidated financial statements for the fiscal year ending September 2026. An additional provision for the loans is expected to be recognized in the non-consolidated financial statements for the fiscal year ending September 2026. |
| Impact on Earnings Forecast | If it becomes necessary to revise the consolidated earnings forecast for the fiscal year ending September 2026, the Company will promptly announce the revision. The earnings forecast for the fiscal year ending September 2027 is scheduled to be announced when the financial results for the fiscal year ending September 2026 are released, incorporating the impact of this matter. |
| Type of litigation or proceeding | Special liquidation under the Companies Act |
| Date of filing / date of action | Early October 2026 (planned filing of a petition to commence special liquidation) |
| Amount of receivables at risk of non-collection or delayed collection | Loans of ¥112.5 million (as of 17 September 2026, owed by アクセルメディカ株式会社) |
| Scheduled resumption date | The specific timing of resumption has not been determined at this time. |
| Outlook | アクセルメディカ株式会社 is scheduled to be excluded from the scope of consolidation when its liquidation is completed. AXEL MARK INC. will take over the Beauty & Wellness business and plans to rebuild it after completing preparations, including obtaining a new manufacturing and marketing license. |
| Planned follow-up disclosure | If it becomes necessary to revise the earnings forecast for the fiscal year ending September 2026, the Company will promptly announce the revision. The earnings forecast for the fiscal year ending September 2027 is scheduled to be announced when the financial results for the fiscal year ending September 2026 are released. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The business continuity of アクセルメディカ株式会社 has become difficult, revenue has remained substantially below plan since its establishment and operating losses have continued. In addition, the company is insolvent and its cash position has deteriorated, creating a risk that further financial support would cause additional damage to the group's financial foundation.